BCL2 and neuroblastoma: In line with this reasoning, activation of the ISR by thapsigargin was also sufficient to downregulate c-MYC, HIF-1α, and MCL-1 in neuroblastoma cells already within 1 h of treatment, whereas BCL-2 levels remained unchanged (Fig. S6a).